{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.4","upperLimit":"15.6","value":"10.9"},{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"6.9","value":"3.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"222"}],"units":"Participants"}],"description":"OR was defined as the best overall response of confirmed complete response (CR) or partial response (PR) by BICR assessment as per RECIST v1.1 criteria. As per RECIST v1.1, CR was defined as complete disappearance of all target lesions, with the exception of nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes decreased to normal (short axis \\<10 mm); all target lesions and disease sites were assessed. PR was defined as at least a 30% decrease from baseline in the sum of diameters of all target lesions, non-PD/not evaluated for the non-target lesions and no new lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to receive vepdegestrant 200 mg orally, once daily on Days 1 to 28 of each 28-day cycle. Participants continued to receive assigned treatment until objective disease progression, unacceptable toxicity, death, participant refused further treatment, or one of the other reasons for treatment discontinuation per protocol was met.","id":"OG000","title":"Vepdegestrant"},{"description":"Participants were randomized to receive fulvestrant 500 mg, intramuscularly (injection) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from Cycle 2 Day 1, where 1 cycle = 28 days. Participants continued to receive assigned treatment until objective disease progression, unacceptable toxicity, death, participant refused further treatment, or one of the other reasons for treatment discontinuation per protocol was met.","id":"OG001","title":"Fulvestrant"}],"paramType":"NUMBER","populationDescription":"FAS included all enrolled participants who were randomized. Here, \"Overall Number of Participants Analyzed\" included the participants with measurable disease at baseline (last available assessments collected on or prior to randomization date).","reportingStatus":"POSTED","timeFrame":"From randomization until PD, death or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)","title":"Percentage of Participants With Objective Response (OR) by BICR Assessment- Participants With Measurable Disease at Baseline","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}